<DOC>
	<DOCNO>NCT01642134</DOCNO>
	<brief_summary>The purpose study determine incidence major vascular event ( ischemic haemorrhagics ) third month initiation antithrombotic treatment ( oral anticoagulation dual antiplatelet therapy ) arm follow TAVI .</brief_summary>
	<brief_title>Dual Antiplatelet Therapy Versus Oral Anticoagulation Short Time Prevent Cerebral Embolism After TAVI</brief_title>
	<detailed_description>Transcatheter aortic valve implantation ( TAVI ) procedure use vascular access option proven benefit definitively treatment severe symptomatic aortic stenosis patient consider unsuitable conventional open heart surgery . By avoid hemodynamic effect , cardiovascular cerebral microembolic load cardiopulmonary bypass circulation , assume TAVI procedure beneficial despite risk neurological complication . Currently antithrombotic therapy procedure standardize . International treatment guideline recommend post-operative patient conventional surgical aortic bioprosthesis maintain oral anticoagulation 3 month procedure , unless otherwise note continuation . Whereas study postulate patient aortic bioprostheses , dual antiplatelet therapy effective prevent major cardiac cerebrovascular event oral anticoagulation , low incidence bleed complication 3 month treatment , investigator formulate follow hypothesis : â€¢ There low incidence major cardiac cerebrovascular event patient dual antiplatelet therapy compare patient oral anticoagulation 3 month implantation aortic bioprosthesis TAVI procedure .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Intracranial Embolism</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Adult patient ( 18 year ) ability understand accept participation clinical trial . 2 . Patients symptomatic degenerative severe aortic stenosis reject conventional surgical aortic valve replacement due unacceptably high risk accept TAVI procedure 3 . Signed informed consent . 4 . Patients participate clinical trial research study . 1 . Patients oral anticoagulation treatment 2 . Patients undergo MRI study 3 . Recent stroke &lt; 14 day prior , revascularized coronary artery disease life expectancy &lt; 12 month 4 . Patients proven allergy aspirin , clopidogrel acenocoumarol 5 . Patients TAVI procedure undergo regimen dual antiplatelet therapy oral anticoagulation 3 month due new postTAVI medical indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Antiplatelet</keyword>
	<keyword>Anticoagulation</keyword>
</DOC>